Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
Rhea-AI Summary
Agios Pharmaceuticals (Nasdaq: AGIO), a company focused on cellular metabolism and PK activation therapies for rare diseases, will host its second quarter 2025 financial results conference call and webcast on July 31, 2025, at 8:00 a.m. ET.
The presentation will be available through the company's website investor section, with a replay accessible approximately two hours after the event.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m. ET to report its second quarter 2025 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
Morgan.Sanford@Agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Eamonn.Nolan@Agios.com
FAQ
When is Agios Pharmaceuticals (AGIO) Q2 2025 earnings call?
How can I access Agios Pharmaceuticals (AGIO) Q2 2025 earnings webcast?
Will there be a replay available for Agios (AGIO) Q2 2025 earnings call?
What does Agios Pharmaceuticals (AGIO) specialize in?
